Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: A phase I-II study

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2033-2040

  Genre, Dominique ^a   Viens, P ^a,b   Gravis, G ^a   Bertucci, F ^a   Cowen, D ^a   Novakovitch, G ^a   Dermeche S ^a   Chabannon, C ^a   Oziel Taieb, S ^a   Camerlo, J ^a   Houvenaeghel, G ^a   Jacquemier, J ^a   Maraninchi, D ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Advanced breast cancer; Filgrastime; Peripheral stem cells; Sequential intensive chemotherapy

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARMUSTINE; DEXAMETHASONE; DIAZEPAM; HEMOPOIETIC GROWTH FACTOR; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADVANCED CANCER; ALKYLATION; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DRUG RESPONSE; FEMALE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; OUTPATIENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SOMNOLENCE; VOMITING; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW DISEASES; BREAST NEOPLASMS; CARMUSTINE; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FILGRASTIM; GASTROINTESTINAL DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM METASTASIS; THIOTEPA; TREATMENT OUTCOME;

EID: 0033869627     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Viens P, Penault-Llorca F, Jacquemier J, Gravis G, Cowen D, Bertucci F, Houvenaeghel G, Biaise D and Maraninchi D: High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplantation 21: 249-254, 1998.
2. Viens P, Maraninchi D, Legros M, Oberling F, Philip T, Herve P, Plagne R, Dufour P, Bergerat JP, Guastalla JP, Rozenbaum A and Carcassonne Y: High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplantation 5: 227-233, 1990.
3. Griswold DP Jr., Trader MW, Frei E, III, Peters WP, Wolpert MK and Laster WR Jr: Response of drug-sensitive and resistant L1210 leukemias to high-dose chemotherapy. Cancer Res 47: 2323-2327, 1987.
4. Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F and Resegotti L: Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clinical Oncology 15: 491-498, 1997.
5. Gaspard MH, Maraninchi D, Stoppa AM, Gastaut JA, Michel G, Tuhiana N, Blaise D, Novakovitch G, Rossi JF, Weiller PJ, Sainty D, Horchowski N and Carcassonne Y: Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous hone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemotherapy and Pharmacology 22: 256-262, 1988.
6. Meisenberg B, Miller W and McMillan R: Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC). Bone Marrow Transplantation 18: 1087-1093, 1996.
7. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP and Moore JO: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncology 6: 1368-1376, 1988.
8. Antman KH, Ayash LJ, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE and Frei III E: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncology 10: 102-110, 1992.
9. Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei IE and Antman KH: Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncology 14: 2984-2992, 1996.
10. Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A and Ascensao JL: A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Bone Marrow Transplantation 19: 983-988, 1997.
11. Dillman RO, Barth NM, Nayak SK, DeLeon C, O'Connor A and Morrelli L: High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res Treatment 37: 277-289, 1996.
12. Bearman SI, Overmoyer B, Bolwell B, Taylor C, Shpall EJ, Cagnoni PJ, Mechling B, Ronk B, Baron A, Purdy M, Ross M and Jones RB: High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplantation 20: 931 -937, 1997.
13. Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Baron AE, Ross M, Matthes S, Dunbar SE and Jones RB: High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncology 16: 1661-1668, 1998.
14. Long GD, Negrin RS, Hoyle CF, Kusnierz-Glaz CR, Schriber JR, Blume KG and Chao NJ: Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 76: 860-868, 1995.
15. Tepler I, Cannistra SA, Frei III E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M, Sheets E, Elias AD, Mazanet R, Wheeler C, Ayash L, Schwartz G, McCauley M, Gaynes L, Harvey S, Schnipper LE and Antman KH: Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncology 11: 1583-1591, 1993.
16. Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, Ward DM, Miller L, Christian M and Taetle R: Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncology 10: 464-473, 1992.
17. Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M, Gilewski T, Hudis C, Gulati S and Norton L: Rapid administration of multiple cycles of high- dose myelo-suppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncology 11: 1144-1149, 1993.
18. Crown J and Norton L: Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Annals Oncology 6: S21-S26, 1995.
19. Vahdat L, Raptis G, Fennelly D, Hamilton N, Reich L, Tiersten A, Harrison M, Hudis CA, Moore M, Yao TJ, Norton L and Crown J: Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1: 1267-1273, 1995.
20. Shapiro CL, Ayash LJ, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D and Henderson IC: Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncology 15: 674-683, 1997.
21. Viens P, Gravis G, Genre D, Bertucci F, Cowen D, Camerlo J, Cappiello MA, Conte M, Finaud M, Chabannon C, Houvenaeghel G and Maraninchi D: High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Bone Marrow Transplant 20: 199-203, 1997.
22. van der Wall E, Beijnen JH and Rodenhuis S: High-dose chemotherapy regimens for solid tumors. Cancer Treatment Reviews 21: 105-132, 1995.
23. O'Dwyer PJ, LaCreta FP, Engstrom PF, Peter R, Tartaglia L, Cole D, Litwin S, De Vito J, Poplack D, DeLap RJ and Comis RL: Phase I/pharmacokinetic reevaluation of Thiotepa. Cancer Res 51: 3171-3176, 1991.
24. O'Dwyer PJ, LaCreta FP, Schilder R, Nash S, McAleer C, Miller LL, Hudes GR and Ozols RF: Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncology 10: 1352-1358, 1992.
25. Phillips G, Fay JW, Herzig G, Herzig RH, Weiner R, Wolff S, Lazarus HM, Karanes C, Ross W and Kramer B: Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU), NSC#4366650 and cryopre-served autologous marrow transplantation for refractory cancer. A phase 1-II study. Cancer 52: 1792-1802, 1983.
26. Phillips G, Wolff S, Fay JW, Herzig RH, Lazarus HM, Schold C and Herzig G: Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncology 4: 639-645, 1986.
27. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M and Philip T: High-dose carmustine for high-grade gliomas in childhood. Cancer Chemotherapy and Pharmacology 39: 376-379, 1997.
28. Negrier S, Ranchere J, Philip I, Merrouche Y, Biron P, Biaise D, Attal M, Rebattu P, Clavel M, Pourreau C, Palmer P, Favrot M, Jasmin C, Maraninchi D and Philip T: Intravenous interleukin-2 just after high dose BCNU and autologous hone marrow transplantation. Report of a multicentric French pilot study. Bone Marrow Trans plantation 8: 259-264, 1991.
29. + cell dose and method of mobilization. Blood 84 (suppl. 1) 349A, 1994.
30. + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 19: 303-310 1997.
31. + cell content. Bone Marrow Transplantation 19: 1103-1110, 1997.